Posts Tagged ‘Vaccination’

Origin and differentiation of human memory CD8 T cells after vaccination

The differentiation of human memory CD8 T cells is not well understood. Here we address this issue using the live yellow fever virus (YFV) vaccine, which induces long-term immunity in humans. We used in vivo deuterium labelling to mark CD8 T cells that proliferated in response to the virus and then assessed cellular turnover and longevity by quantifying deuterium dilution kinetics in YFV-specific CD8 T cells using mass spectrometry. This longitudinal analysis showed that the memory pool originates from CD8 T cells that divided extensively during the first two weeks after infection and is maintained by quiescent cells that divide less than once every year (doubling time of over 450 days). Although these long-lived YFV-specific memory CD8 T cells did not express effector molecules, their epigenetic landscape resembled that of effector CD8 T cells. This open chromatin profile at effector genes was maintained in memory CD8 T cells isolated even a decade after vaccination, indicating that these cells retain an epigenetic fingerprint of their effector history and remain poised to respond rapidly upon re-exposure to the pathogen.

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Zika virus (ZIKV) has recently emerged as an explosive pandemic associated with severe neuropathology in newborns and adults1. There are no ZIKV-specific treatments or preventatives; thus, development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic proteins2,3. Here, we demonstrate that a single low-dose intradermal immunization with lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) encoding the pre-membrane and envelope (prM-E) glycoproteins of a 2013 ZIKV outbreak strain elicited potent and durable neutralizing antibody responses in mice and non-human primates. Immunization with 30 μg of nucleoside-modified ZIKV mRNA-LNPs protected mice from ZIKV challenges at 2 weeks or 5 months post-vaccination, and a single dose of 50 μg was sufficient to protect non-human primates from a challenge at 5 weeks post-vaccination. These data demonstrate that nucleoside-modified mRNA-LNPs elicit rapid and durable protective immunity and thus represent a new and promising vaccine candidate for the global fight against ZIKV.

Mummified smallpox virus shows the disease isn’t as old as we thought

The mummy of a young boy discovered buried in a crypt beneath a Lithuanian church contains the oldest-known complete set of smallpox genes, and scientists hope that the discovery will shed new light on the history of the infamous pathogen, according to NPR and BBC News reports. Save for a few secured, frozen samples, smallpox […]

The post Mummified smallpox virus shows the disease isn’t as old as we thought appeared first on Redorbit.

Why it’s time for a rethink on flu vaccination

By Derek Gatherer, Lancaster University I recently had my annual flu shot. Along with all the others who’ve received it, I’ll be hoping that it does the job of preventing me catching flu this winter – or at least reducing the severity of the dise…

Powered by WordPress | Designed by: video game | Thanks to search engine optimization, seo agency and Privater Sicherheitsdienst